Venus Medtech (Hangzhou) Inc
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to tre… Read more
Venus Medtech (Hangzhou) Inc (VMTHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.026x
Based on the latest financial reports, Venus Medtech (Hangzhou) Inc (VMTHF) has a cash flow conversion efficiency ratio of -0.026x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.51 Million) by net assets ($2.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Venus Medtech (Hangzhou) Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Venus Medtech (Hangzhou) Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Venus Medtech (Hangzhou) Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Venus Medtech (Hangzhou) Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hume Industries Berhad
KLSE:5000
|
0.240x |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
0.078x |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
N/A |
|
Tudor Gold Corp
PINK:TDRRF
|
-0.003x |
|
Rumere Co. Ltd.
SHE:301088
|
N/A |
|
Taita Chemical Co Ltd
TW:1309
|
0.035x |
|
ACT Energy Technologies Ltd.
TO:ACX
|
0.026x |
|
Domo Inc
NASDAQ:DOMO
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Venus Medtech (Hangzhou) Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Venus Medtech (Hangzhou) Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.21 Billion | $23.74 Million | 0.011x | +105.14% |
| 2023-12-31 | $2.92 Billion | $-610.02 Million | -0.209x | -4.02% |
| 2022-12-31 | $3.63 Billion | $-729.46 Million | -0.201x | -103.64% |
| 2021-12-31 | $4.63 Billion | $-456.92 Million | -0.099x | -60.54% |
| 2020-12-31 | $3.86 Billion | $-237.00 Million | -0.061x | +25.92% |
| 2019-12-31 | $3.66 Billion | $-303.29 Million | -0.083x | +74.24% |
| 2018-12-31 | $470.37 Million | $-151.47 Million | -0.322x | +68.22% |
| 2017-12-31 | $81.20 Million | $-82.27 Million | -1.013x | -- |